Myelin Foundry | $4,000,000 | (May 9, 2024)
Rad AI | $50,000,000 | (May 9, 2024)
Definely | $7,000,000 | (May 9, 2024)
Vasa Therapeutics
United States
- California
- 04/01/2024
- Seed
- Undisclosed Amount
Vasa Therapeutics is a San Diego-based, private biotechnology company committed to the discovery and development of therapeutics that target pathophysiology of cardiovascular aging.
Vasa Therapeutics has three active preclinical programs:
1. VS-041 is the first personalized medicine-based treatment of HFpEF. VS-041 shows robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. Phase 1 clinical trial of VS-041 is planned for 2024.
2. Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease.
3. A best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.
- Industry Biotechnology Research
- Website https://vasatherapeutics.com/
- LinkedIn https://www.linkedin.com/company/vasa-therapeutics/about/
RunPod | $20,000,000 | (May 9, 2024)
Greenboard | $4,500,000 | (May 9, 2024)
Provable Markets | $8,000,000 | (May 9, 2024)
Lucid Bots | $9,100,000 | (May 9, 2024)
RLP, Rapid Liquid Print | $7,000,000 | (May 9, 2024)
In-House Health | $4,000,000 | (May 9, 2024)
Arbelos Markets | $28,000,000 | (May 9, 2024)
Ciba Health | $10,000,000 | (May 9, 2024)
Panax | $10,000,000 | (May 9, 2024)